Latent Tuberculosis Infection Treatment Practices in Two Large Integrated Health Systems in California, 2009–2018

Evaluation of the Latent Tuberculosis Care Cascade Among Public Health Clinics in the United States

(2022) Samuel B Holzman et al.   CLINICAL INFECTIOUS DISEASES

Development and validation of a prediction algorithm to identify birth in countries with high tuberculosis incidence in two large California health systems

(2022) Heidi Fischer et al.   PLoS One

State-level prevalence estimates of latent tuberculosis infection in the United States by medical risk factors, demographic characteristics and nativity

(2021) Ali Mirzazadeh et al.   PLoS One

Latent Tuberculosis Infection

(2021) Maunank Shah et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of Latent Tuberculosis Infection—An Update

(2019) Moises A. Huaman et al.   CLINICS IN CHEST MEDICINE

Comparing performance between log-binomial and robust Poisson regression models for estimating risk ratios under model misspecification

(2018) Wansu Chen et al.   BMC Medical Research Methodology

Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection

(2018) Andrey S. Borisov et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults

(2018) Dick Menzies et al.   NEW ENGLAND JOURNAL OF MEDICINE

Latent Tuberculosis and Current Health Disparities in California: Making the Invisible Visible

(2018) Shereen Katrak et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA

(2017) Philip A LoBue et al.   LANCET INFECTIOUS DISEASES

Initiation and completion rates for latent tuberculosis infection treatment: a systematic review

(2016) Andreas Sandgren et al.   BMC INFECTIOUS DISEASES

Screening for Latent Tuberculosis Infection in Adults

(2016) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis

(2016) Hannah Alsdurf et al.   LANCET INFECTIOUS DISEASES

Tuberculosis Infection in the United States: Prevalence Estimates from the National Health and Nutrition Examination Survey, 2011-2012

(2015) Roque Miramontes et al.   PLoS One

Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection

(2013) Dick Menzies et al.   ANNALS OF INTERNAL MEDICINE

Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection

(2011) Timothy R. Sterling et al.   NEW ENGLAND JOURNAL OF MEDICINE